Treatment of Advanced Breast Cancer with Tamoxifen

  • C. Rose
  • H. T. Mouridsen
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 91)

Abstract

The overall response rate in advanced breast cancer patients treated with endocrine therapies is in the range of 30% [1, 2]. In recent years it has been demonstrated that response to various forms of endocrine treatment can be predicted in approximately 60% of cases provided that the patient’s tumor tissue contains the estrogen receptor (ER) protein [3]. This response rate is in the same range as that obtained with cytotoxic therapy [1, 2]. Furthermore, a response to endocrine therapy seems to predict that a response to subsequent cytotoxic treatment will be of longer duration and lead to prolonged survival [4, 5]. Another aspect of endocrine therapy is that new remissions can be achieved when using subsequent endocrine therapies [6–11]. Therefore, taking into account the fact that treatment of patients with metastatic disease is, at best, palliative, it appears that there is a sound clinical rationale behind the use of the relatively nontoxic endocrine treatment modalities.

Keywords

Estrogen Hydrocortisone Glucocorticoid Androgen Estradiol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Henderson IC, Canellos GP (1980) Cancer of the breast. N Engl J med 302: 17PubMedCrossRefGoogle Scholar
  2. 2.
    Henderson IC, Canellos GP (1980) Cancer of the breast. N Engl J med 302: 78PubMedCrossRefGoogle Scholar
  3. 3.
    McGuire WL, Pearson OH, Segalof A (1975) Predicting hormone responsivenes in human breast cancer. In: McGuire WL, Carbone PP, Vollmer EP (eds) Estrogen receptors in human breast cancer. Raven, New York, p 17Google Scholar
  4. 4.
    Legha SS, Buzdar AU, Smith TL, Swenerton KD, Hortobagyi GN, Blumenschein GR (1980) Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer 46: 438PubMedCrossRefGoogle Scholar
  5. 5.
    Manni A, Trujillo JE, Pearson OH (1980) Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer: effects on survival. Cancer Treat Rep 64: 111PubMedGoogle Scholar
  6. 6.
    Pearson OH, Ray DS (1959) A comparison of the results of adrenalectomy and hypophysectomy in carcinoma of the breast. In: Raven RW (ed) Cancer hormone therapy, vol 6. Butterworth, London, p 335Google Scholar
  7. 7.
    Manni A, Trujillo JE, Marshall JS, Brodkey J, Pearson OH (1979) Antihormone treatment of stage IV breast cancer. Cancer 43: 444PubMedCrossRefGoogle Scholar
  8. 8.
    Manni A, Pearson OH, Brodkey J, Marshall JS (1979) Transsphenoidal hypophysectomy in breast cancer. Cancer 44: 2330PubMedCrossRefGoogle Scholar
  9. 9.
    Manni A, Arafah BM, Pearson OH (1981) Androgen-induced remissions after antiestrogen and hypophysectomy in stage IV breast cancer. Cancer 48: 2507PubMedCrossRefGoogle Scholar
  10. 10.
    Westerberg H (1980) Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. Cancer Treat Rep 64: 117PubMedGoogle Scholar
  11. 11.
    Smith IE, Harris AL, Morgan M, Ford HT, Gazet J-C, Harmer CL, White H, Parsons CA, Villardo A, Walsh G, McKinna J A (1981) Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J 283: 1432CrossRefGoogle Scholar
  12. 12.
    Dao TL (1972) Ablation therapy for hormone-dependent tumours. Annu Rev Med 23: 1PubMedCrossRefGoogle Scholar
  13. 13.
    Robin PE, Dalton GA (1977) The role of major endocrine ablation. In: Stoll BA (ed) Breast cancer management-early and late. Chicago Year Book, Chicago, p 147Google Scholar
  14. 14.
    Hayward J (1970) Hormones and human breast cancer. Springer, Berlin Heidelberg New York, pp 10, 33 (Recent results in cancer research, vol 24)Google Scholar
  15. 15.
    Dao TL (1978) The value of adrenalectomy in patients with metastatic breast cancer. Surg Clin North Am 58: 801PubMedGoogle Scholar
  16. 16.
    Hayward JL, Atkins HJB, Falconer MA et al. (1970) Clinical trials comparing transfrontal hypophysectomy with adrenalectomy and with transethmoidal hypophysectomy. In: Joslin CAF, Gleave EN (eds) The clinical management of advanced breast cancer. Alpha Omega, Cardiff, p 50Google Scholar
  17. 17.
    Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB (1973) Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31PubMedCrossRefGoogle Scholar
  18. 18.
    Samojlik E, Santen RJ (1978) Adrenal suppression with aminoglutethimide. III. Comparison of plasma A4- and zl5-steroids in postmenopausal women treated for breast carcinoma. J Clin Endocrinol Metab 47: 717PubMedCrossRefGoogle Scholar
  19. 19.
    Samojlik E, Veldhuis JD, Wells SA, Santen RJ (1980) Preservation of androgen secretion during estrogen suppresion with aminoglutethimide in the treatment of metastatic carcinoma. J Clin Invest 65: 602PubMedCrossRefGoogle Scholar
  20. 20.
    Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA (1981) A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305: 545PubMedCrossRefGoogle Scholar
  21. 21.
    Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E (1978) Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47: 1257PubMedCrossRefGoogle Scholar
  22. 22.
    Lippman M, Bolan G, Hoff K (1976) The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36: 4595PubMedGoogle Scholar
  23. 23.
    Zava DT, McGuire WL (1978) Human breast cancer: androgen action mediated by estrogen receptor. Science 199: 787PubMedCrossRefGoogle Scholar
  24. 24.
    Nicholson RL, Davies P, Griffiths K (1978) Interaction of androgens with oestradiol-17/? receptor proteins in DMBA-induced mammary tumours - a possible oncolytic mechanism. Eur J Cancer 14: 439PubMedCrossRefGoogle Scholar
  25. 25.
    Lober J, Rose C, Salimtschik M, Mouridsen HT (1981) Treatment of advanced breast cancer with progestins. Acta Obstet Gynecol Scand [Suppl] 101: 39CrossRefGoogle Scholar
  26. 26.
    Santen RJ, Samojlik E (1979) Medical adrenalectomy for treatment of metastatic breast carcinoma. In: McGuire WL (ed) Breast cancer: advances in research and treatment, vol 3. Plenum, New York, p 79Google Scholar
  27. 27.
    Mouridsen HT, Palshof T, Patterson J, Battersby L (1978) Tamoxifen in advanced breast cancer. Cancer treat Rev 5: 131PubMedCrossRefGoogle Scholar
  28. 28.
    Nicholson RI, Davies P, Griffiths K (1977) Effects of oestradiol-17/? and tamoxifen on nuclear oestradiol-17/3 receptors in DMBA-induced rat mammary tumours. Eur J Cancer 13: 201PubMedCrossRefGoogle Scholar
  29. 29.
    Jordan VC, Dix CJ, Naylor KE, Prestwich G, Rowsby L (1978) Nonsteroidal antiestrogens: their biological effects and potential mechanism of action. J Toxicol Environ Health 4: 363PubMedCrossRefGoogle Scholar
  30. 30.
    Koseki Y, Zava DT, Chamness GC, McGuire WL (1977) Estrogen receptor translocation and replenishment by the anti-estrogen tamoxifen. Endocrinology 101: 1104PubMedCrossRefGoogle Scholar
  31. 31.
    Rochefort H, Borgma JL (1981) Differences between oestrogen receptor activation by oestrogen and anti-oestrogen. Nature 292: 257PubMedCrossRefGoogle Scholar
  32. 32.
    Ip MM, Milholland RJ, Rosen F, Kim U (1981) Dichotomus effects of tamoxifen on a transplantable rat mammary tumour. Cancer Res 41: 984PubMedGoogle Scholar
  33. 33.
    Butler WB, Kelsey WH (1981) Effect of the antiestrogen tamoxifen on synchronized cultures of MCF-7 cells. 17th Annual meeting Am Soc Clin Oncology, Abstr 35Google Scholar
  34. 34.
    Horwitz KB, Kosekiy, McGuire WL (1978) Estrogen control of progesterone receptor in human breast cancer: Role of estrodiol and antiestrogen. Endocrinology 103: 1742PubMedCrossRefGoogle Scholar
  35. 35.
    Namer M, Lalanne C, Baulieu E-E (1980) Increase of progesterone receptor by tamoxifen as a hormonal challenge test in breast cancer. Cancer Res 40: 1750PubMedGoogle Scholar
  36. 36.
    Sutherland RL, Murphy LC (1980) The binding of tamoxifen to human mammary carcinoma cytosol. Eur J Cancer 46: 1141Google Scholar
  37. 37.
    Sutherland RL, Murphy LC, Foo MS, Green MD, Whybourne AM, Krozowski ZS (1980) High- affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature 288: 273PubMedCrossRefGoogle Scholar
  38. 38.
    Furr DJ, Patterson JS, Richardson DN, Slater SR, Wakeling AE (1979) Tamoxifen. In: Goldberg ME (ed) Pharmacological and biochemical properties of drug substances, vol 2. APA, Washington, p 355Google Scholar
  39. 39.
    Patterson JS (1981) Clinical aspects and development of antioestrogen therapy: A review of the endocrine effects of tamoxifen in animals and man. J Endocrinol 89: 67Google Scholar
  40. 40.
    Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Rubens RD (1977) Assesment of response to therapy in advanced breast cancer. Cancer 39: 1289PubMedCrossRefGoogle Scholar
  41. 41.
    Tormey DC, Lippman MF, Edwards BE, Cassidy J (to be published) Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancerGoogle Scholar
  42. 42.
    Tormey DC, Falkson G, Crowley J, Falkson HC, Voelkel J, Davies TE (1982) Dibromodulcitol and adriamycin ± tamoxifen in advanced breast cancer. Cancer Clin Trials 5: 33Google Scholar
  43. 43.
    Ingle JN, Ahmann DL, Green SJ, Edmondson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S (1981) Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304: 16PubMedCrossRefGoogle Scholar
  44. 44.
    Beex L, Pieters G, Smals A, Koenders A, Benraad T, Kloppenborg P (1981) Tamoxifen versus ethinyl estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat Rep 65: 179PubMedGoogle Scholar
  45. 45.
    Cocconi G, Lisi BD, Boni C, Mori P (1981) Chemotherapy vs combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study. UICO conf clin oncol breast cancer, Abstr. 03 - 0141Google Scholar
  46. 46.
    Fabian C, Sternson L, El-Serafi M, Cain L, Harne E (1981) Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 48: 876PubMedCrossRefGoogle Scholar
  47. 47.
    Ward HWC (1973) Anti-oestrogen therapy for breast cancer: A trial of tamoxifen at two-dose levels. Br Med J 1: 13PubMedCrossRefGoogle Scholar
  48. 48.
    Kiang DT, Frenning DH, Vosika GJ, Kennedy BJ (1980) Comparison of tamoxifen and hypophysectomy in breast cancer treatment. Cancer 45: 1322PubMedCrossRefGoogle Scholar
  49. 49.
    Stewart HJ, Forrest APM, Gunn JM, Hamilton T, Langlands AO, McFadyen IJ, Roberts MM (1980) The tamoxifen trial — A doubleblind comparison with stilbestrol in postmenopausal women with advanced breast cancer. Eur J Cancer [Suppl] 1: 83Google Scholar
  50. 50.
    Luporini G, Beratta G, Tabiadon D, Tedeschi L, Rossi A (1981) Comparison between oral medroxyprogesterone acetate (MPA) and tamoxifen (TMX) in advanced breast carcinoma. 17th Annual meeting Am Soc Clin Oncology, Abstr C-398Google Scholar
  51. 51.
    Mattsson W (1980) A phase III trial of treatment with tamoxifen versus treatment with high-dose medroxyprogesterone-acetate in advanced postmenopausal breast cancer. In: Iacobelli S, Marco AD (eds) Role of medroxyprogesterone in endocrine-related tumours. Raven, New York, p 65Google Scholar
  52. 52.
    Lipton A, Harvey HA, Santen RJ, Worgul T, Boucher A, White D (1981) Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. 17th Annual meeting Am Soc Clin Oncology, Abstr. C-437Google Scholar
  53. 53.
    Mouridsen HT, Salimtschik M, Dombernowsky P, Gelshoj K, Palshof T, Rorth M, Daehnfeldt JL, Rose C (1980) Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilbestrol in advanced breast cancer in postmenopausal women. Eur J Cancer [Suppl] 1: 107PubMedGoogle Scholar
  54. 54.
    Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Rawdin RG, Talley RW, Potter NR (1977) Diethylstilbestrol: Recommended dosages for different categories of breast cancer patients. JAMA 237: 2079PubMedCrossRefGoogle Scholar
  55. 55.
    Mouridsen HT, Ellemann K, Mattsson W, Palshof T, Daehnfeldt JL, Rose C (1979) Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 63: 171PubMedGoogle Scholar
  56. 56.
    Powles TJ (1981) Multiple endocrine therapy with tamoxifen, aminoglutethimide and danazol for treatment of patients with metastatic breast cancer. UICC conf clin oncology, Abstr 03 - 0106Google Scholar
  57. 57.
    Settatree RS, Butt WR, London DR, Holme GM, Morrison JM (1979) Tamoxifen and bromocriptine combination in advanced breast cancer. Advances in medical oncology. Research and education, vol 12. Pergamon, New York, p 806 (5)Google Scholar
  58. 58.
    Mouridsen HT, Palshof T, Engelsman E, Sylvester R (1980) CMF versus CMF + tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial. Int Congress SenologyGoogle Scholar
  59. 59.
    Galmarini F, Santos R, Brunu R, Casas O, Chiesa J, Bertacchini C, D’Auria A, Domingoez E (1981) Tamoxifen + CIVEFU vs CIVEFU in advanced breast cancer. UICC conf oncology, Abstr 03 - 0359Google Scholar
  60. 60.
    Boccardo F, Rubagotti A, Sertoli MR, Rosso R (1981) Randomized trial of chemo-hormone therapy in advanced breast cancer. 17th Annual meeting Am Soc Clin Oncology, Abstr. C397Google Scholar
  61. 61.
    Arraztora J, Ramirez G (1981) Chemotherapy with and without hormonal manipulation in the treatment of advanced breast cancer. 17th Annual meeting Am Soc Clin Oncology, Abstr C-401Google Scholar
  62. 62.
    Pritchard KI, Thomson DB, Meakin JW, Myers RE, Sutherland DJA, Mobbs VG, Campbell J (1981) The role of tamoxifen in premenopausal women with metastatic carcinoma of the breast: an update. 17th Annual meeting Am Soc Clin Oncology, Abstr C-405Google Scholar
  63. 63.
    Wada T, Koyama H, Terasawa T (1981) Effect of tamoxifen in premenopausal Japanese women with advanced breast cancer. Cancer Treat Rep 65: 728PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1984

Authors and Affiliations

  • C. Rose
    • 1
  • H. T. Mouridsen
    • 1
  1. 1.Department of Oncology IFinsen InstituteCopenhagenDenmark

Personalised recommendations